Five-year overall survival among patients with metastatic renal cell carcinoma: Results of Russian population-based study RENSUR5.

20 Background: The results of the 5-year overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) has been reported rarely. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapies in mRCC and assess 5-year OS in Russian population. Methods: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St.Petersburg, Ufa). Patients were included if mRCC was diagnosed from January 2010 to January 2011. Anonymised data were collected through an online registry covering demographics, treatments and outcomes. Results: 439 adult mRCC patients were included in the study for analysis. Mean age at diagnosis of mRCC was 60.9 (33-90) years (with 9% of patients aged 375 years). Patients were predominantly male (70.2%), 67.7% had nephrectomy; clear-cell and non-clear cell tumors were detected in 61.1% and 7.7% of patients, respectively. 271 (62%) patients received systemic therapy. Median duration of therapy was 11 months (95% CI 9.5-12.5). The majority of treatment was with interferon only (n=145). 105 (23.9%) patients were treated with targeted therapy. 69 (15.7%) patients received 3 2 treatment lines. Survival outcomes are listed in Table. Conclusions: RENSUR5 is a large 'real-world' database assessing mRCC treatment patterns and 5-year OS in Russia. Based on results of this study, we assume that 5-year OS is poor and should be improved on novel therapies. [Table: see text]